Skip to main content
  • Saved

made a Post

Development of CAR-T cell therapy for B-ALL using a point-of-care approach

Development of CAR-T cell therapy for B-ALL using a point-of-care approach

Source :

https://www.tandfonline.com/doi/full/10.1080/2162402X.2020.1752592

ABSTRACT Recently approved by the FDA and European Medicines Agency, CAR-T cell therapy is a new treatment option for B-cell malignancies. Currently, CAR-T cells are manufactured in centralized facilities and face bottlenecks like complex scaling up, high costs, and logistic operations.